Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-12-2020 | NSCLC | Original Article – Clinical Oncology

First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation

Authors: Thierry Landre, Gaetan Des Guetz, Kader Chouahnia, Boris Duchemann, Jean-Baptiste Assié, Christos Chouaid

Published in: Journal of Cancer Research and Clinical Oncology | Issue 12/2020

Abstract

Purpose

Erlotinib is indicated as first-line treatment for patients with non-small-cell lung cancer (NSCLC) harboring an epidermal growth-factor–receptor (EGFR) mutation. Addition of a vascular endothelial growth factor (VEGF) inhibitor (anti-VEGF) in combination with the tyrosine-kinase inhibitor erlotinib in this setting is controversial.

Methods

We conducted a meta-analysis of randomized trials comparing anti-VEGF plus erlotinib vs erlotinib alone as first-line therapy for advanced NSCLC harboring an EGFR mutation. Outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and median duration of response (DOR). A fixed-effect model was used.

Results

Four studies evaluated bevacizumab + erlotinib (ARTEMIS, NEJ026, J025667, Stinchcombe et al.), and another evaluated ramucirumab + erlotinib (RELAY). These five eligible studies included 1230 non-squamous NSCLC patients, 654 (53.2%) with exon 19 deletion (ex19del) and 568 (46.8%) with EGFR^L858R. Patients were predominantly women (63%), Asians (85%) and non-smokers (60%); the median age was 64 years. The combination (anti-VEGF + erlotinib) was significantly associated with prolonged PFS (hazards ratio [HR] 0.59 [95% confidence interval (CI) 0.51–0.69]; p < 0.00001). The combination achieved significantly longer median DOR (p < 0.005). Based on interim analyses, OS (HR 0.90 [0.68–1.19]; p = 0.45) and ORR (odds ratio 1.19 [95% CI 0.91–1.55]; p = 0.21 were comparable.

Conclusions

For patients with untreated, advanced, EGFR-mutation–harboring NSCLCs, the anti-VEGF + erlotinib combination, compared to erlotinib alone, was associated with significantly prolonged PFS but mature data for OS are needed to confirm the benefit of this strategy.

Akamatsu H, Koh Y, Ozawa Y, Fujimoto D, Hata A, Katakami N, Tomii K, Shimokawa T, Yamamoto N (2018) Osimertinib with Ramucirumab in EGFR-mutated, T790M-positive patients with progression during EGFR-TKI therapy: phase Ib study. Clin Lung Cancer 19(6):e871–e874. https://doi.org/10.1016/j.cllc.2018.08.001CrossRefPubMed

Akamatsu H, Teraoka S, Morita S, Katakami N, Tachihara M, Daga H, Yamamoto N, Nakagawa K (8715L) Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive patients with progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L). Clin Lung Cancer 20(4):e492–e494. https://doi.org/10.1016/j.cllc.2019.03.002CrossRefPubMed

Castellanos E, Feld E, Horn L (2017) Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer. J Thoracic Oncol 12(4):612–623. https://doi.org/10.1016/j.jtho.2016.12.014CrossRef

Gridelli C, Rossi A, Ciardiello F, De Marinis F, Crinò L, Morabito A, Morgillo F et al (2016) BEVERLY: rationale and design of a randomized open-label phase III trial comparing bevacizumab plus erlotinib vs erlotinib alone as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small-cell lung cancer. Clin Lung Cancer 17(5):461–465. https://doi.org/10.1016/j.cllc.2016.04.001CrossRefPubMed

Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, Vlahovic G, Soh C-H, O’Connor P, Hainsworth J (2011) Efficacy of bevacizumab plus erlotinib vs erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet (London, England) 377(9780):1846–1854. https://doi.org/10.1016/S0140-6736(11)60545-XCrossRef

Kitagawa C, Kada A, Saito AM, Ichinose Y, Saka H (2019) Rationale and design of a randomized phase 2 trial of gefitinib plus bevacizumab vs gefitinib alone in patients with epidermal growth factor receptor mutant non-squamous non-small-cell lung cancer: study protocol. Kurume Med J 65(2):77–81. https://doi.org/10.2739/kurumemedj.MS652001CrossRefPubMed

Li X-Y, Lin J-Z, Shu-Han Yu (2020) Front-line therapy in advanced non-small cell lung cancer with sensitive epidermal growth factor receptor mutations: a network meta-analysis. Clin Ther. https://doi.org/10.1016/j.clinthera.2019.12.006CrossRefPubMed

Maemondo M, Tatsuro F, Haruhiro S, Naoki F, Kana W, Shunichi S, Shunichiro I et al (2020) NEJ026: final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations. J Clin Oncol 38(15):9506–9506. https://doi.org/10.1200/JCO.2020.38.15_suppl.9506CrossRef

Nakagawa K, Edward BG, Takashi S, Makoto N, Santiago PA, Luis P-A, Chao HC et al (2019) Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(19)30634-5CrossRefPubMed

Ninomiya T, Ishikawa N, Inoue K, Kubo T, Yasugi M, Shibayama T, Maeda T et al (2019) Phase 2 study of afatinib alone or combined with bevacizumab in chemonaive patients with advanced non-small-cell lung cancer harboring EGFR mutations: AfaBev-CS study protocol. Clin Lung Cancer 20(2):134–138. https://doi.org/10.1016/j.cllc.2018.10.008CrossRefPubMed

Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C et al (2020) Overall survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382(1):41–50. https://doi.org/10.1056/NEJMoa1913662CrossRefPubMed

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B et al (2017) Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med 5(5):435–444. https://doi.org/10.1016/S2213-2600(17)30129-7CrossRefPubMed

Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y et al (2019) Erlotinib plus bevacizumab vs erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol 20(5):625–635. https://doi.org/10.1016/S1470-2045(19)30035-XCrossRefPubMed

Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N et al (2014) Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 15(11):1236–1244. https://doi.org/10.1016/S1470-2045(14)70381-XCrossRefPubMed

Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Eng J Med 378(2):113–125. https://doi.org/10.1056/NEJMoa1713137CrossRef

Stinchcombe TE, Jänne PA, Wang X, Bertino EM, Weiss J, Bazhenova L, Lin Gu et al (2019) Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.1847CrossRefPubMedPubMedCentral

Wu Y-L, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F et al (2017) Dacomitinib vs gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 18(11):1454–1466. https://doi.org/10.1016/S1470-2045(17)30608-3CrossRefPubMed

Zhang S, Mao X-D, Wang H-T, Cai F, Jing Xu (2016) Efficacy and safety of bevacizumab plus erlotinib vs bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis. BMJ Open 6(6):e011714. https://doi.org/10.1136/bmjopen-2016-011714CrossRefPubMedPubMedCentral

Zhao B, Zhang W, Dongliang Yu, Jianjun Xu, Wei Y (2018) Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials. Lung Cancer (Amsterdam, Netherlands) 122:10–21. https://doi.org/10.1016/j.lungcan.2018.05.011CrossRef

Zhou Q, Wu Y-L, Cheng Y, Liu Y, Chen G, Cui J, Yang N et al (1480OCTONG) 1480OCTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated chinese patients with advanced EGFR-mutated NSCLC. Ann Oncol. https://doi.org/10.1093/annonc/mdz260.002CrossRefPubMedPubMedCentral

Zhou K, Zhao S, Guo W, Ding L (2020) Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer: a systematic review and meta-analysis. Medicine 99(3):e18771. https://doi.org/10.1097/MD.0000000000018771CrossRefPubMedPubMedCentral

Title: First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation
Authors: Thierry Landre
Gaetan Des Guetz
Kader Chouahnia
Boris Duchemann
Jean-Baptiste Assié
Christos Chouaid
Publication date: 01-12-2020
Publisher: Springer Berlin Heidelberg
Keywords: NSCLC
Lung Cancer
Lung Cancer
Tyrosine Kinase Inhibitors
NSCLC
Lung Cancer
Tyrosine Kinase Inhibitors
Erlotinib
Osimertinib
Bevacizumab
Ramucirumab
Published in: Journal of Cancer Research and Clinical Oncology / Issue 12/2020
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-020-03311-w

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2020

Patient expectations are better for immunotherapy than traditional chemotherapy for cancer

Clinical characteristics and comparison of the outcome in young versus older patients with upper gastrointestinal carcinoma

Surgical outcomes of second primary lung cancer after the extrapulmonary malignancy

EPS15–NTRK1: a novel NTRK1 oncogenic fusion in patient with lung adenocarcinoma

Deciphering the role of Wnt signaling in acute myeloid leukemia prognosis: how alterations in DNA methylation come into play in patients’ prognosis

Ascitic Calprotectin as an early predictor of hepatocellular carcinoma in patients with cirrhotic ascites

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page